Methods and analysis:
This is a retrospective individually-matched case-control study among a cohort of Australian children born from 1997 to 1999, the period of transition from wP to aP vaccines; we include in the cohort children listed on Australia's comprehensive population-based immunisation register as having received a first dose of either pertussis vaccine by 16 weeks old. 500 cohort children diagnosed as having IgE-mediated food allergy at specialist allergy clinics will be included as cases. Controls matched to each case by date and jurisdiction of birth and regional socioeconomic index will be sampled from the immunisation register. Conditional logistic regression will be used to estimate odds ratio (±95%CI) of receipt of wP (versus aP) as the first vaccine dose among cases compared to controls. 
Ethics and dissemination:

Trial Registration Details: NCT02490007, status: enrolling
Strengths and limitations of this study
• The transition from wP to aP in Australia represents a natural experiment of the effect of infant pertussis vaccination on subsequent food allergy on a scale not achievable by a randomised controlled trial.
• The study is nested within Australia's comprehensive, prospective, population-based immunisation register, meaning that ascertainment of vaccination status is likely to be accurate and any misclassification is likely to be non-differential for cases and controls.
• We included only cases diagnosed as IgE-mediated food allergy in specialist tertiary allergy clinics.
• Not all children diagnosed with IgE-mediated food allergy had a formal food challenge, the gold-standard for diagnosis.
• We assume that the probability of receipt of Wp as the first pertussis vaccine dose (rather than Ap) was dependent on date and jurisdiction of birth, but independent of any other risk factors for food allergy. It is not possible to verify this assumption is valid. 
INTRODUCTION:
Epidemiology of atopic disease in Australia and internationally: As a group, atopic diseases (eczema, asthma, rhinoconjunctivitis, food allergy) are now the most prevalent chronic diseases of children in resource-rich industrialised countries; at least one in four Australian children is affected by these conditions (1) . Whereas the incidence of aero-allergic atopic diseases (asthma and rhinoconjunctivitis) began rising several decades ago and peaked in Australia in the 1980s (2) , since the late 1990s a 'second wave' of non-aero allergic atopy has emerged characterised by severe IgE-mediated food allergies in children(3). For example, one Australian allergy clinic observed a 12-fold rise in consultations for food allergy in children between 1995 and 2006(4). Fatal food anaphalaxis rose almost 10% per year from 1997 to 2013 (5) . In the most comprehensive study of its kind, the prevalence of food sensitisation among 12 month old Victorian infants was 18% (95% CI, 17-19%), with 10% having challenge-proven food allergy (6) . The most common allergies were to peanut 3.0%, raw egg 8.9%, and sesame 0.8%. The prevalence of allergic eczema among infants was found to be even higher, 26.7% (95% CI 25.0-28.4%) (6) . A similar phenomenon has also been described in the United Kingdom(7) and the United States (8, 9) . A characteristic feature of this epidemic has been the onset of symptoms in early infancy and persistence of symptoms into adolescence(3).
The rise in atopic disease, and sudden rise in food allergy in particular, suggest one or more causal environmental triggers. It has been widely suggested that lifestyle change, in particular declining exposure to infection -the hygiene hypothesis(10) -is responsible. However, this does not by itself explain the more abrupt onset of food-related allergy in Australia (11) .
A temporal association exists between the onset of the epidemic of food allergies in Australia and the transition from the use of vaccines containing the whole cell pertussis antigen (wP) to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 27917345_File000006_645550512.docx 20/11/2017 those containing the acellular pertussis antigen (aP). Use of aP began to replace that of wP in the mid 1990s and by early 1999 most scheduled childhood pertussis vaccines were aP (12) .
In the United States and in the United Kingdom, a temporal association between the phasing out of wP vaccines and the increase in hospitalisations for food allergy is not clear (unpublished data, personal communication) although coding of hospitalisation records for allergies may be both insensitive and non-specific so any associations could be easily obscured. In light of the contrasting immunological effects of wP compared with aP (reviewed below), it is plausible that a causal relationship underlies the ecological association observed in Australia.
The immunological basis of atopic disease:
A reciprocal relationship exists between Thelper cell type 1 and type 2 (Th1 and Th2) immunity due to cross-regulation of their respective effector cell populations (13) . The balance between Th1 and Th2 is established during early infancy. Atopy is caused by a dysregulation of this balance in the developing immune system, characterised by an immune phenotype that is heavily biased toward Th2-immunity or 'Th2-polarised', the consequent over-production of IgE to one or more allergens, and IgE-mediated inflammation.
The developing immune system appears most susceptible to Th2 polarisation in the critical early months after birth. This period is pivotal in the transition from the Th1-suppressed/Th2-dominant phenotype needed to avoid rejection in utero, to a more Th1/Th2 balanced phenotype. Newborns are exposed to an array of new antigenic proteins from infection and other natural environmental exposures, including gut flora and food components. The development of tolerance to these natural exposures represents an early challenge to the developing immune system. It appears the development of tolerance can be influenced by a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (19) . The most recent meta-analysis of vaccine efficacy comparing wP and aP estimate efficacy at 94% ((95% CI, 88%-97%) and 84% (95% CI, 81%-87%) respectively (20) . Moreover, a number of studies detail the Th2 immune bias induced in some infants who received aP-only schedules, resulting in excessive IgE production against vaccine antigens (21, 22) . A recent study has shown that the Th polarisation induced by infant immunisation can persist into adolescence and adulthood and is maintained after booster vaccination (23) . This could be due to the combined effect of: 1) carry-over of the Th2-biased in utero phenotype; 2) the presence of alum and pertussis toxin, which have Th2-adjuvantising properties; and 3) the absence of the balancing Th1- stimulating ligands present in wP. These effects manifest especially among children with evidence of an underlying Th2-skewed phenotype (21, 22) .
The broader immuno-modulating properties of pertussis: The Th2 polarising effect of the intial dose of aP appears to extend beyond vaccine-specific responses; there may be a significant "bystander" effect with up-regulation of circulating IgE to a broad range of antigens following subsequent doses of aP. Importantly, these Th2-stimulatory effects appear to extend to food allergens (24) , especially in early infancy when immune memory against allergens is most susceptible to programming (25, 26) . The administration of additional pertussis vaccine doses in later childhood in children primed with aP-only is associated with frequent injection-site reactions. In Australia, this contributed to the removal of the 18 month old pertussis booster given in 2003, which in turn led to reduced protection against pertussis among pre-school aged children (27) . These adverse reactions have been linked to the presence of high levels of vaccine-specific, Th2-polarised, Th-memory cells (28) . Children primed with aP-only also exhibit high titres of total IgE, including tetanus-specific (29, 30) and pertussis-specific IgE (29) . These responses are rarely observed among children who have received wP containing vaccines, including those who have received mixed vaccine schedules of wP and aP (31) . A recent study of a birth cohort examined the effect of delaying aP vaccination on atopic outcomes. This study found that delay of aP by 1 month resulted in a reduction in eczema in infants and use of eczema medications (32) . To date, no other studies have found a relationship between aP vaccines and allergy. A study from the 1990s found no significant difference in overall rates of skin prick test reactivity or allergic disease among young Swedish children who received wP compared to those who received aP (33) . In that study population the frequency of food allergy was low (~2%) compared to that observed among contemporary Australian infants. A more recent prospective birth cohort of children 20/11/2017 from the Isle of Wight also failed to find any difference in the frequency of atopic outcomes among children receiving wP versus aP (34) .
Based on these observations, we speculate that removal of wP from the infant vaccine schedule has contributed to the observed rise in IgE-mediated food allergy among Australian infants.
AIM
To assess the possible food allergy-preventive benefit of using wP compared with aP for pertussis vaccination in childhood.
OBJECTIVES AND OUTCOME MEASURES
Primary objective
To determine if Australian children born between 1997 to 1999 (inclusive) who received wP as their first pertussis vaccine dose in infancy were less likely to subsequently develop IgEmediated food allergy compared with contemporaneous children who received aP as their first pertussis vaccine dose.
Secondary objectives
(I) To determine if Australian children born in the years 1997 to 1999 (inclusive) who received at least one dose of a wP pertussis vaccine at any age were less likely to subsequently develop IgE-mediated food allergy compared with contemporaneous children who received only aP pertussis vaccines. 
METHODS AND ANALYSIS
Primary Outcome Measure
The primary outcome is IgE-mediated food allergy diagnosed by a registered specialist paediatric allergist.
Definition of exposure of interest (vaccination)
For the primary analysis, exposure is defined as Australian Immunisation Register (AIR) documented receipt of either a wP containing vaccine or receipt of an aP containing vaccine as the first vaccine against pertussis and given before age 16 weeks (strictly <112 days) irrespective of any subsequent pertussis vaccinations.
For the secondary analyses, exposure is defined as either:
AIR documented receipt of one or more doses of wP at any age or only aP containing vaccines for all pertussis vaccinations. All other sequences of vaccines will be coded as nonapplicable and excluded from the analysis.
(II) AIR documented receipt of only wP containing vaccine for all pertussis vaccinations or only aP containing vaccines for all pertussis immunisations. All other sequences of vaccines will be coded as non-applicable and excluded from the analysis.
Vaccination status for each case and its corresponding matched controls is referenced from the age of allergy diagnosis in the case.
Study Setting
Cases are drawn from private allergy clinics and from allergy clinics associated with tertiary teaching hospitals in the Australian states of New South Wales, Victoria, South Australia and Western Australia; matched cohort controls are selected from among children registered as resident in the same state and recorded as having received at least one pertussis vaccine dose on the population-based vaccine register (AIR).
Participant Identification
Eligibility criteria
All cases and cohort controls must be registered on AIR as having had a first dose of any pertussis containing vaccine before age 16 weeks and during the period in which the transition from wP to aP vaccine occurred: 1 st January 1997 to 31st December 1999. 
Case definition
Cases are considered to have IgE-mediated food allergy on the basis of 1) a documented history of consistent clinical symptoms following ingestion of an implicated food, and 2)
evidence of sensitisation to that food via either positive skin-prick test or elevated specific
IgE to the implicated food, with onset after the first pertussis-containing vaccine but before age 15 years.
To meet the case definition of IgE-mediated food allergy, the case must satisfy BOTH: where evidence of sensitisation must be at the time of consultation or within 6 months after the clinical encounter.
Other acceptable terms:
When reviewing case histories the below terms are considered synonymous:
a. urticaria -hives, rash, welts The case definition has been agreed upon by specialist allergists associated with the study as consistent with international expert consensus for the definition of IgE-mediated food allergy.
Determination of exposure (vaccination)
The primary exposure of interest for case and cohort controls is the first received pertussis A waiver of consent was sought and approved on the basis that the study poses negligible risk to participants and that seeking individual consent for access to data was unfeasible and may lead to ascertainment bias.
STATISTICS
Sample size and power considerations
A study involving 500 sets of cases and controls, with 10 matched controls for each case, has 80% power to detect a 23% lower risk (odds ratio 0.77) of food allergy among children who received wP as their first dose of pertussis vaccine compared with those who received aP as their first dose. This assumes that: (i) 50% of cohort controls receive a first pertussis vaccine dose of wP on average; (ii) the correlation coefficient for exposure (first dose of wP) between cases and matched controls is 0.5; and (iii) a two-sided significance level of 5%. We believe that a smaller effect size will not influence vaccine policy.
Bias
Management of confounding:
Because routine vaccines in Australia are delivered almost exclusively via the National Immunisation Program, date of birth (and therefore date of vaccination) and jurisdiction are considered to be the only relevant factors associated with vaccine type received (wP versus aP), and therefore the only relevant potential confounders.
We will minimise confounding by these factors by direct matching. In so far as the type of vaccine received is expected to be independent of ethnicity, sex, family size, birth order, pet ownership and all other factors putatively or known to be related to food allergy, there are unlikely to be any other relevant confounders of the association between vaccine type and allergy; inability to match or adjust for other factors poses negligible threat to study validity.
Minimising information bias:
The case definition is intended to be pragmatic and yet specific for IgE-mediated food allergy, excluding many non-allergic food reactions potentially misclassified as allergy by non-specialists and in hospital coding. For completeness, we will conduct an a priori sensitivity analyses which will include as cases only those children meeting the case definition who also have 1) challenge-proven food allergy and 2) evidence of sensitisation at or higher than the following levels: SPTs: 8 mm for cow milk, 7 mm for egg, and 8 mm peanut, or IgE serum responses: 15kU/L for cow milk, 7 kU/L for egg, 14kU/L for peanut. These are the documented levels for 95%PPV as defined by Sporik et al (35) and Sampson (36) . Ascertainment of vaccination status will be from the AIR for both cases and controls and will not rely on either parental recall or recording in medical records.
The AIR record of cases will only be ascertained after verification from the site PI that the case definition is fully met. Children with food allergy will be excluded as cases if they are not registered on AIR. There is no reason to expect that the accuracy or completeness of AIR should be different for cases and controls, so any inaccuracy is likely to be non-differential.
Minimisation of selection bias:
Cases are sampled only from among children presenting to specialist-led private allergy clinics and allergy clinics at tertiary paediatric centres. To ensure correct classification of cases, we will not sample cases from non-tertiary Australian hospitals, from cases diagnosed and managed by non-specialists, or those without confirmation of sensitisation. We nonetheless expect cases will be generally representative of all Australian children with true IgE-mediated food allergy in the birth cohort. Cohort controls will be sampled from date-of-birth, jurisdiction and socioeconomic index matched children from the AIR, a comprehensive population-based register of all Medicare-registered children in Australia. Because cohort controls are sampled at random, they will provide an 
Description of Statistical Methods
The study population characteristics will be summarised by case or control status using frequency and proportion for categorical or binary variables, means and standard deviations for symmetric continuous distributions and medians and inter-quartile ranges for asymmetric distributions. Conditional logistic regression will be used to perform hypothesis tests of the association between pertussis vaccine type (wP or aP) and IgE-mediated food allergy. Results will be summarised using odds ratios (OR's) and presented with associated 95% confidence intervals. Because controls will be sampled from the AIR irrespective of past or future case status, the odds ratio will be considered to be an unbiased estimator of the relative risk of food allergy among children receiving wP compared with aP vaccine.
Analysis of Outcome Measures
Primary analysis population: All case and control individuals recorded on the AIR as receiving at least one dose of pertussis vaccine before age 16 weeks will be included in the primary analysis, irrespective of whether they received any further doses of pertussis vaccine.
Primary analysis:
Conditional logistic regression will be used to evaluate the association between receipt of wP versus aP as the first pertussis vaccine and diagnosis of IgE-mediated food allergy. Direct matching will be on date of birth (+/-7 days), jurisdiction (Australian state or territory), and IRSAD decile of the most recent Medicare-listed postcode (1 st to 10 th ); no factors or interactions will be adjusted for in the a priori analysis. For the primary analysis, a child's exposure will be coded as either:
aP1: first pertussis vaccine dose of aP, with subsequent doses either wP or aP or none or wP1: first pertussis vaccine dose of wP, with subsequent doses either wP or aP or none
The comparison of primary interest will be between aP1 and wP1 vaccinated children.
Secondary analyses population:
As for the primary analysis population, however the comparison of wP-only and aP-only vaccinated children (secondary analysis II) will exclude any children who received a mixture of aP and wP vaccines.
Secondary analyses:
As for the primary analysis to evaluate the association between pertussis vaccines received (wP-only or mixed wP/aP in any combination, compared to aP-only) and IgE-mediated food allergy.
For secondary analyses: (I), a child's exposure will be coded as either:
aP_only: all pertussis vaccine doses as aP, none as wP or wP_mix: at least 1 dose of wP at any age.
The comparison of interest is between aP-only and at least one dose of wP vaccine. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
The comparison of interest is between aP-only and wP-only vaccinated children. All mixed aP/wP vaccinated children will be excluded from the analysis. Table 1 provides a summary of the coding of exposure for the primary and secondary.
Any analyses other than those outlined above or in the sensitivity analyses and case subgroup analysis below will be declared as unplanned and post hoc. 
Matching procedures
For each identified case, up to ten children will be randomly sampled without replacement from the AIR database from among all children born on the same day as the case +/-7 days, and from the same jurisdiction and from a postcode with the same IRSAD decile (1 st to 10 th ).
Children will only be included once as a case. Each cohort control will be associated with one unique case. Consistent with the case-cohort method(37), sampling of controls will be from the register cohort without regard to case status (i.e. children will be eligible to be a control 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
irrespective of whether they are at any stage a case). In total up to 5,000 controls will be sampled. IRSAD deciles will be ascertained from ABS data from the 2011 census since it is likely that only the most recent Medicare postcode is available for the majority of the participants.
Sensitivity analysis
In the first instance, a sensitivity analysis will be performed on the case definition for the primary analysis based on confirmation of food allergy via a food challenge. Confirmation by food challenge is considered the gold standard for food allergy, but in clinical practice this has more usually been reserved for cases in which there is diagnostic uncertainty or to confirm resolution of the food allergy. If there is a significant change in the interpretation of the results based on the sensitivity analysis compared to the primary analysis, then further sensitivity analyses will also be performed for the secondary analyses.
As an additional sensitivity analysis, the case definition will require documentation of a skin prick test (SPT) wheal of 8 mm for cow milk, 7 mm for egg, or 8 mm peanut, or food-specific serum IgE of 15kU/L for cow milk, 7 kU/L for egg, or 14kU/L for peanut. These more conservative cut-offs correspond to almost 100% and 95% positive predictive value (PPV) of IgE-mediated allergy for the SPT and ss-IgE respectively.
.
Case sub-group analysis
To investigate the potential heterogeneity of responses following exposure to specific vaccine formulations, we will conduct an a priori subgroup analysis by acellular vaccine brand (excluding children who have received mixed acellular vaccine types). All other subgroup analyses will be declared as unplanned and post hoc.
DISCUSSION
Allergy represents a significant disease burden in developed countries. The temporal association between an apparent increase in severe food allergy and the replacement of whole cell with acellular pertussis vaccine in Australia warrants further investigation. Food allergy is not only important in its own right, it is also associated with eczema and with asthma (4-fold increased risk) in later childhood (38, 39) .
This study has been designed to comply with both the STROBE recommendations and also the more specific recommendations put forward by Sharpe et al (40) for case-cohort studies.
The strengths of this study include objective allergy definition, and access to an established The disadvantages of this study are that it is reliant on existent databases for which there is little way to assess the validity or accuracy of data entry. The AIR database has been lauded as a highly effective means of tracking vaccination in the Australian population, however there is evidence of under reporting of administered vaccines (41) , and there has been no 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
